Importantly, pharmacological restoration of cytoskeletal tension (e.g., via calyculin A administration (79)) has been shown to reverse IL-1β-driven catabolism by reestablishing physiological tension homeostasis, highlighting targeted modulation of tenocyte mechanobiology as a promising therapeutic strategy for counteracting inflammatory degradation in tendinopathy. Here, IL1B is linked to disease of the tendon.